Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment
Ya-Li Luo,Yan Li,Wen Zhou,Si-Yu Wang,Yong-Qi Liu
DOI: https://doi.org/10.2147/dddt.s415453
2023-09-02
Abstract:Ya-Li Luo, &ast Yan Li, &ast Wen Zhou, Si-Yu Wang, Yong-Qi Liu Gansu University Key Laboratory for Molecular Medicine and Chinese Medicine Prevention and Treatment of Major Diseases, Gansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yong-Qi Liu, School of Basic Medicine, Gansu University Key Laboratory for Molecular Medicine and Chinese Medicine Prevention and Treatment of Major Diseases, Gansu University of Chinese Medicine, Lanzhou, People's Republic of China, Email Due to the complex mechanism and limited treatments available for pulmonary fibrosis, the development of targeted drugs or inhibitors based on their molecular mechanisms remains an important strategy for prevention and treatment. In this paper, the downstream signaling pathways mediated by VEGFR and LPAR1 in pulmonary cells and the role of these pathways in pulmonary fibrosis, as well as the current status of drug research on the targets of LPAR1 and VEGFR2, are described. The mechanism by which these two pathways regulate vascular leakage and collagen deposition leading to the development of pulmonary fibrosis are analyzed, and the mutual promotion of the two pathways is discussed. Here we propose the development of drugs that simultaneously target LPAR1 and VEGFR2, and discuss the important considerations in targeting and safety. Keywords: idiopathic pulmonary fibrosis, VEGFR2, LPAR1 Idiopathic pulmonary fibrosis(IPF) is a progressive, irreversible, disease with high mortality, and current treatment outcomes are limited. Molecular mechanisms of pulmonary fibrosis are complex. Symptoms of IPF include cough and dyspnoea. IPF is the most common Idiopathic interstitial pneumonia (IPF), and its incidence rate and prevalence are increasing. 1 The average life expectancy after IPF diagnosis is 3–5 years. 2 Although international guidelines recommend consideration of lung transplantation in certain patient populations, pirfenidone and nintedanib, multiple tyrosine kinase inhibitors, have been reported to slow disease progression and have recently been approved for use in patients with IPF. The side effects of oral pirfenidone and nintedanib lead to a great impact on the quality of life of patients. 3,4 The side effect of Nintedanib is the adverse reaction of gastrointestinal tract, such as diarrhea. The research shows that 60% of patients have nausea within the first three months of Nintedanib treatment, and the intensity of these side effects is mild or moderate, which can be controlled. 5 Therefore, there remains a need for effective new therapies to treat IPF. There is been development of single target drugs, multitarget drugs or similar drugs for the treatment of IPF. 6 Discovering therapeutic targets related to IPF can promote further slowing down or ideally stopping the progression of IPF. Researchers have been pushing for the screening of candidate targets to accelerate drug therapy for IPF, such as Phosphoinoside 3-kinase/mammalian target of rapamycin inhibitor. However, because IPF involves multiple targets, there are still some deficiencies in targeted therapy with a single target. 7,8 Lysophosphatidic acid (LPA) is a key lipid signaling molecule that regulates a series of very diverse cell events, such as motility, chemotaxis, cell cycle progression, vitality and wound healing. 9 LPA participates in chronic wound healing through LPAR1, as well as idiopathic pulmonary fibrosis. 10 Vascular endothelial growth factor A (VEGF-A) is essential for normal alveolar formation, rapid alveolar proliferation, and normal development of blood vessels during lung maturation. 11 Its receptor, VEGFR2, is considered to be the main signal transduction receptor of VEGF biological activity, and is essential for normal development. 12 Studies have shown that VEGF and LPA mediate downstream pathways by binding VEGFR2 and LPAR1, the corresponding receptors in lung tissue cells, and participate in vascular leakage, collagen deposition and other processes that underlie the continuous progression of pulmonary fibrosis. 13,14 Recent studies on the development of drugs targeting VEGFR2 and LPAR1 for the treatment of pulmonary fibrosis have been reported. 15,16 Current clinical medication of pulmonary fibrosis shows that there are limitations in the effect of single target drugs, and the use of multiple drugs can lead to increased adverse reactions, increased treatment costs and other drawbacks; 17,18 as a result, the research and development of drugs with multi-target onsets of action has practical application prospects. At present, it is not known if LPA-LPAR1 and VEGF-VEGFR2 have an associat -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal